10-Q: Prestige Consumer Healthcare Reports Q3 2025 Results: Revenue Slightly Up, Focus Remains on Managing Costs and Debt
Quarterly Report
Prestige Consumer Healthcare's Q3 2025 results show a slight revenue increase and continued efforts to manage economic uncertainties and debt.
Summary
- Prestige Consumer Healthcare Inc. reported its results for the quarter ended December 31, 2024.
- Total revenues increased by 2.7% to $290.3 million compared to $282.7 million in the same quarter last year.
- North American OTC Healthcare segment revenues increased by 1.0%, while International OTC Healthcare segment revenues increased by 11.3%.
- Gross profit increased by 2.0% to $161.0 million, but gross profit margin decreased to 55.5% due to increased supply chain costs.
- Net income was $61.0 million, compared to $53.0 million in the same period last year.
- Basic earnings per share were $1.23, and diluted earnings per share were $1.22.
- The company repurchased shares of its common stock during the quarter.
- The company expects economic conditions to remain volatile and uncertain, impacting prices and supply.
- The company is managing global supply chain constraints, inflation, and potential outbreaks of severe illnesses.
- The company repaid the balance of its 2012 Term B-5 Loans under the term loan due 2028.
Sentiment
Score: 6
Explanation: The sentiment is neutral. While revenue and net income increased, the decrease in gross profit margin and the acknowledgement of economic uncertainties temper the positive aspects. The company is managing its debt and capital structure, but faces ongoing challenges.
Positives
- Total revenues increased by 2.7% for the quarter ended December 31, 2024.
- International OTC Healthcare segment showed strong revenue growth of 11.3%.
- Net income increased to $61.0 million.
- The company successfully repaid the balance of its 2012 Term B-5 Loans.
- The company is actively managing its capital structure through share repurchases.
Negatives
- Gross profit margin decreased to 55.5% due to increased supply chain costs.
- North American OTC Healthcare segment revenue growth was modest at 1.0%.
- The company acknowledges ongoing economic uncertainty and potential disruptions.
Risks
- Economic uncertainty, including global supply chain constraints and inflation, could affect demand and costs.
- Shortages and delays from third-party manufacturers, particularly in eye care products, could negatively impact sales.
- Reliance on key customers like Walmart and Amazon concentrates revenue and increases risk.
- Disruptions at the distribution center or manufacturing facilities could impair the ability to distribute products.
- Dependence on third-party manufacturers without long-term contracts could lead to supply issues or price increases.
- Foreign currency exchange rate fluctuations could impact pre-tax income.
Future Outlook
The company expects economic conditions to remain volatile and uncertain, impacting prices and supply, and continues to monitor pending legislation and implementation by countries and to evaluate the potential impact on our business in future periods.
Industry Context
The company operates in the competitive OTC healthcare market, facing competition from branded and store brand products, and is adapting to changing consumer trends such as increased online shopping.
Comparison to Industry Standards
- It is difficult to compare Prestige Consumer Healthcare's results directly to industry standards without specific competitor data.
- However, companies like Perrigo, Church & Dwight, and Sanofi (Consumer Healthcare) are key players in the OTC market.
- Benchmarking against these companies would require a deeper analysis of their respective financial results and market positions.
- Perrigo, for example, focuses on store-brand OTC products, while Prestige emphasizes branded products.
- Church & Dwight has a broader portfolio including household products, and Sanofi's consumer healthcare division is part of a larger pharmaceutical company.
- Therefore, a direct comparison requires careful consideration of business models and market segments.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Operating Officer | None | Christine Sacco | 2025-01-06 | New appointment |
Legal Proceedings
- The company is involved from time to time in legal matters and other claims incidental to our business.
- We believe the reasonably possible losses from resolution of routine legal matters and other claims incidental to our business will not have a material effect on our financial statements.
Stakeholder Impact
- Shareholders: Impacted by share repurchases and overall financial performance.
- Employees: Affected by stock-based compensation and company performance.
- Customers: Potentially impacted by supply chain disruptions and product availability.
- Suppliers: Subject to ongoing negotiations and potential price increases.
- Creditors: Impacted by debt repayment and compliance with financial covenants.
Key Dates
| Date | Description |
|---|---|
| 2005 | Board of Directors adopted the 2005 Long-Term Equity Incentive Plan |
| 2012-01-31 | Original date of the asset-based revolving credit facility (2012 ABL Revolver) |
| 2014-06 | Board of Directors approved, and in July 2014, stockholders ratified, an increase of an additional 1.8 million shares of common stock for issuance under the 2005 Plan |
| 2020-06-23 | Board of Directors adopted the Prestige Consumer Healthcare Inc. 2020 Long-Term Incentive Plan (the 2020 Plan). |
| 2020-08-04 | The 2020 Plan became effective, upon the approval of the 2020 Plan by our stockholders. |
| 2024-02-29 | Date of annual impairment review. |
| 2024-05-06 | Company's Board of Directors authorized the repurchase of up to $300.0 million of the Company's issued and outstanding common stock. |
| 2024-10-01 | Acquisition of Hydralyte intellectual property. |
| 2024-10-01 | Entered into Amendments 3 and 4 extending the Master Logistics Services Agreement with GEODIS Logistics LLC |
| 2024-12-02 | Mary Beth Fritz adopted a Rule 10b5-1 Trading Arrangement |
| 2024-12-31 | End of the quarterly period. |
| 2025-01-06 | Christine Sacco appointed Chief Operating Officer and granted 21,136 RSUs. |
| 2025-01-31 | Date for outstanding shares of common stock. |
| 2025-02-06 | Date of report. |
| 2025-03-31 | Fiscal year end. |
| 2025-06-30 | Expiration date of Mary Beth Fritz's Rule 10b5-1 Trading Arrangement |
Keywords
Prestige Consumer Healthcare, OTC Healthcare, Financial Results, Revenue, Gross Profit, Net Income, Share Repurchase, Debt Repayment, Economic Uncertainty, Supply Chain
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.